Citigroup Begins Coverage on Zoetis (NYSE:ZTS)

Equities researchers at Citigroup started coverage on shares of Zoetis (NYSE:ZTS) in a research report issued on Wednesday, Marketbeat Ratings reports. The firm set a “buy” rating and a $145.00 price target on the stock. Citigroup’s price target points to a potential upside of 19.65% from the company’s previous close.

Other analysts also recently issued reports about the stock. Bank of America boosted their target price on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Morgan Stanley set a $160.00 price target on Zoetis in a research report on Thursday, December 18th. Finally, William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Seven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $152.25.

Zoetis Stock Performance

ZTS stock opened at $121.19 on Wednesday. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The company has a market capitalization of $50.98 billion, a price-to-earnings ratio of 20.01, a P/E/G ratio of 1.84 and a beta of 0.98. Zoetis has a 12 month low of $113.29 and a 12 month high of $172.23. The firm has a 50 day moving average of $121.83 and a two-hundred day moving average of $126.65.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities analysts anticipate that Zoetis will post 6.07 EPS for the current fiscal year.

Institutional Trading of Zoetis

Hedge funds have recently bought and sold shares of the stock. Halbert Hargrove Global Advisors LLC boosted its holdings in Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares during the period. Global Wealth Strategies & Associates bought a new stake in Zoetis in the 4th quarter valued at $25,000. Prosperity Bancshares Inc bought a new stake in Zoetis in the 4th quarter valued at $25,000. Lodestone Wealth Management LLC bought a new stake in Zoetis in the 4th quarter valued at $30,000. Finally, KERR FINANCIAL PLANNING Corp bought a new stake in Zoetis in the 3rd quarter valued at $31,000. 92.80% of the stock is owned by institutional investors.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.